Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5PATM)

• Drug Name: PMID24900538C2c Drug Info
• Synonyms: GTPL8138; BDBM50392791; US8486966, 1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 59627005
  TTD Drug ID: DM5PATM

Molecule-Related Drug Atlas

Drug(s) Targeting Salt-inducible kinase 1 (SIK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HG-9-91-01	DM8FD3Z	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Tyrosine-protein kinase BTK (ATK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibrutinib	DMHZCPO	Mantle cell lymphoma	2A85.5	Approved	[3]
Acalabrutinib	DM7GCVW	leukaemia	2A60-2B33	Approved	[4]
Zanubrutinib	DMJWRQP	Mantle cell lymphoma	2A85.5	Approved	[5]
Pirtobrutinib	DMRG1X3	Non-hodgkin lymphoma	2B33.5	Approved	[6]
GDC-0853	DMBEL3Q	Multiple sclerosis	8A40	Phase 3	[7]
ICP-022	DMU72KL	Chronic lymphocytic leukaemia	2A82.0	Phase 3	[8]
Tolebrutinib	DML19V6	Multiple sclerosis	8A40	Phase 3	[9]
CC-292	DMJR9H0	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[10]
BMS-986142	DMZB8AJ	Rheumatoid arthritis	FA20	Phase 2	[7]
LOU064	DME8O5K	Chronic idiopathic urticaria	EB00.1	Phase 2	[11]

Drug(s) Targeting Fibroblast growth factor receptor 1 (FGFR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[12]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[13]
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[14]
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[15]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[16]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[17]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[18]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[19]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[20]
AM-001	DMGVQI8	Actinic keratosis	EK90.0	Phase 2	[21]

Drug(s) Targeting Tyrosine-protein kinase Fgr (FGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID15546730C2	DMOPUIH	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting NT-3 growth factor receptor (TrkC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[23]
Larotrectinib	DM26CQR	Solid tumour/cancer	2A00-2F9Z	Approved	[24]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[25]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[26]
PMID28270021-Compound-WO2016054807Example1	DMD5QEL	Chronic pain	MG30	Patented	[27]
PMID28270010-Compound-Figure24-b	DM0QHLK	N. A.	N. A.	Patented	[26]
Pyrrolo[2,3-d]pyrimidine derivative 4	DME0WSR	Chronic pain	MG30	Patented	[27]
3-amino-5-benzyl-substituted indazole derivative 1	DMFDURZ	Chronic pain	MG30	Patented	[27]
PMID28270010-Compound-Figure5-1	DM2YAPJ	N. A.	N. A.	Patented	[26]
PMID28270021-Compound-WO2015042088Example4	DM6KXOQ	Chronic pain	MG30	Patented	[27]

Drug(s) Targeting Fms-like tyrosine kinase 3 (FLT-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[28]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[29]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[13]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[30]
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[24]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[31]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Approved	[28]
Quizartinib	DM8Y4JS	Acute myeloid leukaemia	2A60	Approved	[20]
Lestaurtinib	DMQ2AIJ	Acute myeloid leukaemia	2A60	Approved (orphan drug)	[32]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[33]

Drug(s) Targeting ABL messenger RNA (ABL mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
G-1128	DMHOMFK	Chronic myelogenous leukaemia	2A20.0	Discontinued in Phase 2	[34]
PP121	DMU8KTO	Discovery agent	N.A.	Investigative	[35]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[36]
PMID23441572C24	DMG4MLA	Discovery agent	N.A.	Investigative	[37]
GNF-5	DMGLIPV	Discovery agent	N.A.	Investigative	[38]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ABL messenger RNA (ABL mRNA)	TT6B75U	ABL1_HUMAN	Inhibitor	[1]
Fibroblast growth factor receptor 1 (FGFR1)	TTRLW2X	FGFR1_HUMAN	Inhibitor	[1]
Fms-like tyrosine kinase 3 (FLT-3)	TTGJCWZ	FLT3_HUMAN	Inhibitor	[1]
NT-3 growth factor receptor (TrkC)	TTXABCW	NTRK3_HUMAN	Inhibitor	[1]
Phosphorylase kinase testis gamma 2 (PHKG2)	TTI5WS6	PHKG2_HUMAN	Inhibitor	[1]
Salt-inducible kinase 1 (SIK1)	TT1H6LC	SIK1_HUMAN	Inhibitor	[1]
Testis-specific serine kinase 2 (TSSK2)	TTA3Z2W	TSSK2_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase Fgr (FGR)	TTPOGS1	FGR_HUMAN	Inhibitor	[1]
WNK lysine-deficient protein kinase 3 (WNK3)	TTI7FDX	WNK3_HUMAN	Inhibitor	[1]

References

• [1] Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
• [2] Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16986-91.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
• [4] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [6] Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of InnoCare Pharma.
• [9] Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738.
• [10] Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [13] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [15] Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
• [16] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [17] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
• [19] AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)
• [22] Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [24] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [25] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [26] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [27] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
• [29] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [30] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [31] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [32] Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
• [33] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [34] Pharmaceutical Design And Development: A Molecular Biology Approach, T V Ramabhadran, 2005. Page(219).
• [35] Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
• [36] Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
• [37] Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. J Med Chem. 2013 Apr 11;56(7):3033-47.
• [38] Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463(7280):501-6.